|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
BCG and IL - 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method-stability analysis.
|
31499716 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P < .0001), tumor grade (P = .001), T staging (P < .0001), N staging (P = .002), cancer specific survival (P < .0001), overall survival (P < .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through "Coagulation," "Hypoxia," "Apical junction," "Ultraviolet response," "Epithelial mesenchymal transition," "Angiogenesis," "KRAS (KRAS proto-oncogene, GTPase) signaling,"Complement,"IL2-STAT5-signaling," "Inflammatory response," "IL6-JAK-STAT3-signaling," "Myogenesis," "TNF α signaling," "Apoptosis," and "Hedgehog-signaling.
|
29517678 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
In previous studies, it has been shown that the granulocyte macrophage-colony stimulating factor (GM-CSF) or interleukin-2 (IL-2) surface modified MB49 bladder cancer stem cells (MCSCs) vaccine could induce a specific antitumor immunity and against bladder cancer in mice model respectively.
|
28205361 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
RT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-α and IFN-γ markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P<0.05), but had no significant effect in non-tumor SV-HUC-1 cells.
|
28599483 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
In genito-urinary tumors immunotherapy has been administered for a long time: Calmette-Guèrin Bacillus as adjuvant treatment in high risk patients with non muscle invasive urothelial bladder cancer and interleukin-2 and interferon-α in metastatic kidney cancer.
|
28113097 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the effect of -330T/G polymorphism of the IL-2 gene on the development of bladder cancer in the Chinese population.
|
22242968 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
DC/SLC-IL-2 can promote DC proliferation, while TC-DC/SLC-IL-2 and TC-DC/SLC could strongly enhance significant cytotoxicity against bladder cancer cell that was induced by the coculture of DCs (transfected with SLC and IL-2) and TC.
|
19832038 |
2009 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer.
|
10070868 |
1999 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Biomarker
|
disease |
BEFREE |
Treatment of tumor-bearing animals with IL-2-secreting MBT-2 cells was superior to the use of cisplatin, a chemotherapeutic agent used in the treatment of bladder cancer.
|
8459207 |
1993 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Combined therapy of interleukin 2 with cyclophosphamide or bacillus Calmette-Guérin against implanted bladder cancer cells in mice.
|
1949363 |
1991 |
|
Malignant neoplasm of urinary bladder
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette Guerin and systemic interleukin 2.
|
3495671 |
1987 |